New drug cocktail aims to beat back tough leukemia

NCT ID NCT05305859

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing a combination of three drugs—venetoclax, chidamide, and azacitidine—in 30 adults with acute myeloid leukemia that has relapsed or not responded to prior treatment. The goal is to see if this combo can safely improve remission rates and survival. Participants must be 18 or older and have adequate organ function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax, chidamide, and azacitidine (drug combination)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat acute myeloid leukemia that has come back or not responded to standard therapy.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination may cause side effects and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE REFRACTORY LEUKEMIA RELAPSED ADULT AML

Contacts and locations

Locations

Bing Xu
RECRUITING

Xiamen, Fujian, 361003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.